Ex-DeepMind scientist launches AI biotech Latent Labs with $50M
Simon Kohl turned an internship at Google DeepMind into a key role in building AlphaFold2, the Nobel Prize-winning AI model that predicts the structure of proteins. Now, Kohl is venturing out on his...
View ArticleRoche sends experimental CNS drugs to Newleos, a new biotech backed with $93.5M
Newleos Therapeutics emerged Thursday with $93.5 million and a bundle of oral small molecules that it licensed from Roche, further demonstrating that the pharma-to-startup pipeline for CNS drugs is...
View ArticleHunger-suppressing biotech Aardvark raises $94M in IPO
Aardvark Therapeutics, a biotech looking to address hunger rather than appetite for metabolic diseases, will go public on Thursday with a $94 million debut on the Nasdaq. The San Diego-based biotech...
View ArticleSanofi faces $250M charge after J&J-partnered vaccine flunks late-stage test
Sanofi has been hit with a $250 million impairment charge after an E. coli vaccine candidate it was developing with Johnson & Johnson failed to clear a Phase 3 study. An independent data monitoring...
View ArticleNeumora replaces CEO with ex-chief Berns after trial failure
In a surprise move Thursday, Neumora remade its executive team and brought back its former CEO, following last month's failure of the brain health biotech's first big clinical test. Paul Berns, who ...
View ArticleIdorsia’s Tryvio licensing negotiations collapse amid cash squeeze
Idorsia’s plan to hand over the global rights to its blood pressure drug Tryvio has ended in disappointment after a deal announced in November fell through. The Swiss drugmaker said Thursday ...
View ArticleAllay Therapeutics raises $45M for ongoing Series D; Encoded’s layoffs
Plus, news about Pliant Therapeutics, Blueprint Medicines, Galapagos and Atai: Pain biotech raises $45M: Allay Therapeutics, which is developing non-opioid analgesics pain drugs, held the first close...
View ArticleSyngene CEO departs; Lilly and AdvanCell sign radiotherapy partnership
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. The CEO of India-based CDMO Syngene, Jonathan Hunt, has left the role...
View ArticleAgios’ Pyrukynd succeeds in key trial of rare red blood cell disorder in kids
Agios' blood disease treatment Pyrukynd passed a Phase 3 study in PK deficiency in children who do not regularly receive blood transfusions. The readout arrives after Pyrukynd last year failed to meet ...
View ArticleKennedy is confirmed by Senate as Trump's HHS secretary
The Senate on Thursday confirmed Robert F. Kennedy Jr. as Secretary of Health and Human Services, putting a longtime anti-vaccination advocate at the helm of the nation’s health agencies that monitor...
View ArticleKnownwell is betting on in-person weight management care
Knownwell, the Andreessen Horowitz and Flare Capital Partners-backed metabolic health and primary care startup, is adding six locations in the Chicago area. It’s the latest addition to its in-person...
View ArticleDavid Baker lab makes de novo enzymes with AI
The lab of Nobel laureate David Baker keeps pushing the limits of what's possible in making proteins with computers, opening up new possibilities in using AI to make drugs. The latest advance
View ArticleLabs fear future funding cuts with Trump administration actions in limbo
A series of actions by President Donald Trump's administration have provoked profound anxiety among academic labs that undergird biomedical research. These policies — including slashing overhead...
View ArticleUpdated: Moderna earnings: Losses narrow as biotech cuts costs
Moderna is working on restoring investors' faith that its Covid-19 vaccine was not a one-hit-wonder. It also has to show it can get its costs under control. On Friday, the company announced...
View ArticleBristol Myers’ Opdualag stumbles in late-stage resected melanoma trial
Bristol Myers Squibb’s LAG-3/PD-1 targeting immunotherapy Opdualag failed to boost survival in patients with advanced skin cancer in a Phase 3 study, marking the latest flop for an approach that has a...
View ArticleDavid Schenkein resigns from Agios’ board; Moderna hires Roivant exec as...
David Schenkein will step down from Agios Pharmaceuticals’ board of directors at the end of the month "to devote more time to his other commitments," according to its earnings report Thursday. He will...
View ArticleHow Bain’s $3.3B deal for a centuries-old Japanese pharma came to fruition
About two and a half years before they sealed a $3.3 billion deal, Bain Capital and its life sciences team started courting the leadership of Tanabe Pharma and its parent Mitsubishi Chemical ...
View ArticleBioNTech vets raise about $90M in Series A for bispecific immunology research
A new immunology biotech closed its Series A, and it’s backed by investors intricately familiar with the industry. Bambusa Therapeutics said Friday that it raised “approximately” $90 million in the...
View ArticleOtsuka makes pipeline changes; Oculis reveals $100M offering
Plus, news about Aardvark’s IPO: Otsuka cuts cancer programs: The drugmaker is stopping development of OPB-111077, an oral STAT inhibitor, for hematological cancers in the US. It also terminated...
View Article#ASCOGU: Corbus shares dip on mixed Phase 1 solid tumor data for Nectin-4 ADC
Corbus Pharmaceuticals reported encouraging early-stage results for its Nectin-4 targeting ADC in various types of cancer, but a lack of response in certain patients caused shares to slide. The...
View Article